David Hollander - 01 Feb 2022 Form 4 Insider Report for KIORA PHARMACEUTICALS INC (KPRX)

Role: Director
Signature: /s/ Sarah Romano, Attorney-in-Fact*
Issuer symbol: KPRX
Transactions as of: 01 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 03 Feb 2022, 18:02:55 UTC
Previous filing: 23 Dec 2021
Next filing: 08 Feb 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KPRX	Stock Option (right to buy)	Award	$0	+4,000		$0.000000	4,000	01 Feb 2022	Common Stock	4,000	$0.7700	Direct	F1
transaction	KPRX	Stock Option (right to buy)	Award	$0	+5,000		$0.000000	5,000	01 Feb 2022	Common Stock	5,000	$0.7700	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan in connection with the Reporting Person's appointment to the Issuer's Board of Directors. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.
F2	The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2023.

Content

The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan in connection with the Reporting Person's appointment to the Issuer's Board of Directors. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2023.